Professor Kendrick Davis and colleagues from the University of California, Riverside have developed measurement and mapping survey technology that is easy to use, pictorial based, and written by a design that ensures present and ongoing scale validation with Unicode for standardization across virtually all electronic platforms. The emoji-based measurement system (Eb-MS) consists of a linked/connected set of tables organized by three master sets, and sets of linked tables as domain families (i.e., Medicine, Education, etc.) This technology is advantageous because it may facilitate effective communication with individuals with certain health situations, such as stroke, brain injury, or vocal impairments, or with language barriers. 

Professor Min Xue and colleagues from the University of California, Riverside have developed a new method of construction of a bicyclic peptide library featuring a novel stereo-diversified structure and a simplified construction strategy.  MYC inhibitors were synthesized to demonstrate this method. The method works by using a tandem ring-opening metathesis (ROM) and ring-closing metathesis (RCM) reaction (ROM-RCM) to cyclize the linear peptide library in a single step. This technology is advantageous because the resulting bicyclic peptide may be easily linearized for MS/MS sequencing with a one-step chemistry procedure. 

Professor Anubhuti Goel and colleagues from the University of California, Riverside have developed a novel diagnostic tool and software program that provides a quick, objective measure of sensory issues for individuals with Autism spectrum disorders and Fragile X syndrome. This tool works by using a software application to administer a game. Based on the individual’s score at the end of the game, a diagnosis about sensory issues may be made. This technology is advantageous because it may provide an easily accessible, low cost, and safe diagnostic tool for Fragile X Syndrome and Autism that can be developed as a telehealth diagnostic tool.      

Prof. John Franchak and his team have developed a prototype system that accurately classifies an infant's body position.

Brief description not available

Brief description not available

Brief description not available

Professor Min Xue and his lab at the University of California, Riverside have developed a novel hydrophilic endocytosis-promoting peptide (EPP6) rich in hydroxyl groups with no positive charge that may be used for drug delivery purposes. This peptide is non-toxic and has been shown to transport a wide array of small-molecule cargos into a diverse panel of cells. It enables oral administration and absorption through the intestinal lining, and crosses the BBB in vivo. UCR EPP6 is advantageous over existing technologies since it is nontoxic, efficiently enables oral absorption and transport across the BBB.  Fig 1: A) Structure of the UCR EPP. B) Confocal images showing that EPP6 was able to transport different cargo molecules into the cells. C) Orally administered EPP6 is absorbed by the intestines, entering the blood circulation and reaching the brain.  

Researchers at the University of California, Riverside (UCR) in collaboration Nationwide Children’s Hospital  have developed and characterized small peptidomimetics that act as EphA4 agonists. Given ALS is a heterogeneous disease, astrocytes reprogrammed from the fibroblasts of patients with sporadic and SOD1-linked ALS (iAstrocytes) were cultured with MNs and the UCR/Nationwide EphA4 agonists.  As seen in Fig. 1, these small agonistic peptidomimetics decrease MN death in iAstrocytes derived from sporadic ALS (sALS) cells.     

Prof. Mona Eskandari, whose research is known for seminal strides in experimental characterization and computational modeling of lung structural mechanics using novel techniques developed in her lab, has discovered a new method for measuring pulmonary function. It works by analyzing the change in temporal pressure while a patient is holding their breath. The measurement device is simple, comfortable and error-free for the patient to self-administer. Algorithms are used to transform the detailed lung data collection into actionable metrics for early detection capabilities for medical intervention and prevention. The discovery could provide more accessible, detailed, timely, and actionable data on lung function compared to conventional and currently used methods. Fig 1: The medical device prototype being tested in the laboratory  Fig 2: Preliminary data exhibiting detectable differences between several healthy and diseased mice lungs when utilizing the proposed new pulmonary function method

Brief description not available

Prof. Sean Cutler and colleagues at the University of California, Riverside have engineered a system and methods to induce gene expression in plants and organisms, including mammals, using the chemical compound mandipropamid. Using the PYR/PYL/HAB1 promoter system, the PYR1/HAB1 system is reprogrammed to be activiated with mandipropamid.  When the PYR1/HAB1 system dimerizes through chemical induced dimerization (CID) with mandipropamid, the system functions as a control switch for gene expression. This technology has been demonstrated to advantageously accelerate citrus breeding.  It may be applied to improve CAR T-cell therapy and agricultural crops. Fig 1: UCR’s PYR1/HAB1 system is programmed through chemical induced dimerization (CID) initiated by mandipropamid to function as a switch for agrochemical control of gene expression.  

Brief description not available

Professor Ameae Walker from the University of California, Riverside, Professor Srividya Swaminathan from the City of Hope Beckman Research Institute and their colleagues have developed a method for the prevention and treatment of B cell lymphomas. This technology works by systemically inhibiting expression of one form of the set of cell surface molecules that allow cells to respond to prolactin. This highly specific technology suppresses the deleterious downstream effects of prolactin that promote and sustain abnormal B cells. This invention is advantageous compared to existing technologies: all measures in mouse models and analysis of human cells suggest it is nontoxic and therefore will have significantly fewer, if any, side effects. It may also be used together with anti-psychotics that elevate prolactin. Finally, the technology includes a method for screening populations susceptible to development of DLBCL and other B lymphomas for early signs of disease. Antimaia Acts at Three Stages of B Lymphoma Development: 1) Antimaia, a splice modulating oligonucleotide (SMO) that decreases expression of the long form of the prolactin receptor, reduces the number of premalignant cells and the formation of abnormal antibody-producing cells. This also improves the symptomatology of autoimmune disease. 2) Antimaia prevents the conversion of premalignant to overt malignant B cells. 3) Antimaia kills B lymphoma cells. Antimaia works by reducing the number of long and intermediate form prolactin receptors (LF/IF PRLR) without effect on short receptors (SFPRLR). PRL, prolactin; Bcl2, B cell lymphoma 2; Myc, a proto-oncogene.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Researchers from the University of California, Riverside have identified novel protease inhibitory mAbs including MMP-12, MMP-14, BACE-1, Alp2, and cathepsin mAbs. Matrix metalloproteinases MMP-12 and MMP-14 are involved in normal physiological processes, such as embryonic development, reproduction, and tissue remodeling, as well as in disease processes, such as arthritis and metastasis. This technology is significant because these proteases precisely control a wide variety of physiological processes and thus are important drug targets for use in therapy for a wide range of diseases. Fig 1: Selection windows for the UCR cdMMP-14 inhibitors. β-lactamase TEM-1 was modified by insertion of the protease specific cleavage peptide sequences (shown in parentheses) between Gly196 and Glu197 of TEM-1.  

Brief description not available